GLPwatch
Papers (12034)
Page 27 of 201, ranked by citation count.
- Self-assembled glycol chitosan nanogels containing palmityl-acylated exendin-4 peptide as a long-acting anti-diabetic inhalation system.
- Improvement in psoriasis after treatment with the glucagon-like peptide-1 receptor agonist liraglutide.
- Exenatide induces frataxin expression and improves mitochondrial function in Friedreich ataxia.
- The Effect of Semaglutide and GLP-1 RAs on Risk of Nonarteritic Anterior Ischemic Optic Neuropathy.
- New therapies for obesity.
- Significant Decrease in Alcohol Use Disorder Symptoms Secondary to Semaglutide Therapy for Weight Loss: A Case Series.
- Estimated minimum prices and lowest available national prices for antiobesity medications: Improving affordability and access to treatment.
- Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical trial.
- Glucagon-like Peptide-1 Receptor Agonists and Cardiovascular Events: Class Effects versus Individual Patterns.
- Liraglutide, the glucagon-like peptide-1 receptor agonist, has anabolic bone effects in diabetic Goto-Kakizaki rats.
- Association of Glucagon-Like Peptide-1 Receptor Agonists With Optic Nerve and Retinal Adverse Events: A Population-Based Observational Study Across 180 Countries.
- Preventive effects of exenatide on endothelial dysfunction induced by ischemia-reperfusion injury via KATP channels.
- The glucagon-like peptide-1 receptor agonist, liraglutide, attenuates the progression of overt diabetic nephropathy in type 2 diabetic patients.
- A Long-Acting PYY<sub>3-36</sub> Analog Mediates Robust Anorectic Efficacy with Minimal Emesis in Nonhuman Primates.
- Targeting redox imbalance in neurodegeneration: characterizing the role of GLP-1 receptor agonists.
- Semaglutide and Diabetic Retinopathy Risk in Patients with Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials.
- Incretin-based therapies and acute pancreatitis risk: a systematic review and meta-analysis of observational studies.
- Effects of GLP-1 receptor agonist on changes in the gut bacterium and the underlying mechanisms.
- Exendin-4 and Liraglutide Attenuate Glucose Toxicity-Induced Cardiac Injury through mTOR/ULK1-Dependent Autophagy.
- Semaglutide for the treatment of antipsychotic-associated weight gain in patients not responding to metformin - a case series.
- Obesity and cardiovascular disease: An executive document on pathophysiological and clinical links promoted by the Italian Society of Cardiovascular Prevention (SIPREC).
- Dose-finding results in an adaptive, seamless, randomized trial of once-weekly dulaglutide combined with metformin in type 2 diabetes patients (AWARD-5).
- Biochemical, pharmaceutical and therapeutic properties of long-acting lithocholic acid derivatized exendin-4 analogs.
- Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years.
- Combination therapy with liraglutide and insulin in Japanese patients with type 2 diabetes: A 36-week, randomized, double-blind, parallel-group trial.
- One-Year Weight Reduction With Semaglutide or Liraglutide in Clinical Practice.
- Effects of incretin hormones on beta-cell mass and function, body weight, and hepatic and myocardial function.
- Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes.
- Novel strategy for oral peptide delivery in incretin-based diabetes treatment.
- Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year.
- Longer-term liraglutide administration at the highest dose approved for obesity increases reward-related orbitofrontal cortex activation in response to food cues: Implications for plateauing weight loss in response to anti-obesity therapies.
- Clinical Perspectives on the Use of Subcutaneous and Oral Formulations of Semaglutide.
- Gender-related different effects of a combined therapy of Exenatide and Metformin on overweight or obesity patients with type 2 diabetes mellitus.
- Exendin-4 inhibits growth and augments apoptosis of ovarian cancer cells.
- Stimulation of glucagon-like peptide-1 receptor through exendin-4 preserves myocardial performance and prevents cardiac remodeling in infarcted myocardium.
- A pilot randomized controlled trial of liraglutide 3.0 mg for binge eating disorder.
- Liraglutide 3.0 mg for Weight Management: A Population Pharmacokinetic Analysis.
- The Neuroprotective Effect of Liraglutide is Mediated by Glucagon-Like Peptide 1 Receptor-Mediated Activation of cAMP/PKA/CREB Pathway.
- Liraglutide suppresses TNF-α-induced degradation of extracellular matrix in human chondrocytes: a therapeutic implication in osteoarthritis.
- Exenatide therapy in insulin-treated type 2 diabetes and obesity.
- Impact of glucagon-like peptide-1 receptor agonists on adiponectin concentrations: A meta-analysis of randomized controlled trials.
- Glucagon-like Peptide-1 Receptor Agonists and Suicidal Ideation: Analysis of Real-Word Data Collected in the European Pharmacovigilance Database.
- Tirzepatide ameliorates spatial learning and memory impairment through modulation of aberrant insulin resistance and inflammation response in diabetic rats.
- Efficacy and Safety of Tirzepatide in Overweight and Obese Adult Patients with Type 1 Diabetes.
- Effect of Oral Semaglutide on the Pharmacokinetics of Lisinopril, Warfarin, Digoxin, and Metformin in Healthy Subjects.
- Comparison of the glucagon-like-peptide-1 receptor agonists dulaglutide and liraglutide for the management of diabetes in solid organ transplant: A retrospective study.
- Cardiovascular benefits of GLP-1 agonists in type 2 diabetes: a comparative review.
- The treatment of hidradenitis suppurativa with the glucagon-like peptide-1 agonist liraglutide.
- The key role of a glucagon-like peptide-1 receptor agonist in body fat redistribution.
- Postprandial hypoglycaemia after Roux-en-Y gastric bypass and the effects of acarbose, sitagliptin, verapamil, liraglutide and pasireotide.
- Dual GIP/GLP-1 receptor agonists: New advances for treating type-2 diabetes.
- Effect of liraglutide on expression of inflammatory genes in type 2 diabetes.
- The anti-diabetic drug exenatide, a glucagon-like peptide-1 receptor agonist, counteracts hepatocarcinogenesis through cAMP-PKA-EGFR-STAT3 axis.
- Efficacy of Semaglutide by Sex in Obesity-Related Heart Failure With Preserved Ejection Fraction: STEP-HFpEF Trials.
- Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis.
- Safety and efficacy of IDegLira titrated once weekly versus twice weekly in patients with type 2 diabetes uncontrolled on oral antidiabetic drugs: DUAL VI randomized clinical trial.
- FDA-Approved Pharmacotherapy for Weight Loss Over the Last Decade.
- Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study.
- GLP‑1R agonists ameliorate peripheral nerve dysfunction and inflammation via p38 MAPK/NF‑κB signaling pathways in streptozotocin‑induced diabetic rats.
- Mechanistic insights into the effects of quercetin and/or GLP-1 analogue liraglutide on high-fat diet/streptozotocin-induced type 2 diabetes in rats.